# Acasti Pharma (ACST) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ACST
## Company Profile
- Ticker: ACST
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Canada and trades in the U
## Stock Data
- Close: Not available
- Market cap: Not available
## Business Overview
### Late-Stage Cerebrovascular Company
Grace Therapeutics is a late-stage biopharmaceutical company developing GTx-104, a novel intravenous formulation of nimodipine for aneurysmal subarachnoid hemorrhage.
### Clinical Role of GTx-104
Oral nimodipine is the current standard of care in aSAH, but critically ill patients may face swallowing difficulties, inconsistent absorption, interrupted dosing, and challenges in managing hypotension. GTx-104 is designed to provide more controlled nimodipine exposure through peripheral intravenous infusion.
### Reformulation and Regulatory Strategy
GTx-104 applies a new intravenous formulation to an established active ingredient with a well-understood role in aSAH care. The program’s value proposition depends on demonstrating that controlled hospital administration can address practical limitations of oral nimodipine without changing the underlying therapeutic mechanism.
### STRIVE-ON Evidence
The Phase 3 STRIVE-ON safety trial compared GTx-104 with oral nimodipine. The study reported a 19% lower incidence of clinically significant hypotensive events with GTx-104, alongside favorable observations in dose intensity, 90-day functional outcomes, and selected intensive-care resource measures.
## Why The Stock Is Moving

Current closing-price context is not available for ACST.

## Future Catalysts

- Resubmission of the GTx-104 NDA after completion of manufacturing remediation, technology-transfer, and stability requirements.

## Drug Assets

- GTX-104

## Recent News
- 2026-09-03 12:00 EST — [Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference](https://biopharmsignal.com/news/ACST/grace-therapeutics-to-participate-in-the-h-c-wainright-28th-annual-global-invest-be522ee4) — Source: Acasti Pharma
- 2026-08-13 12:00 EST — [Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update](https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-first-quarter-2027-financial-results-provides-busin-6a79ee7b) — Source: Acasti Pharma
- 2026-08-05 01:00 EST — [Grace Therapeutics Announces $10 Million Private Placement](https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-10-million-private-placement-f65d0314) — Source: Acasti Pharma
- 2026-07-28 11:00 EST — [Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration](https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-receipt-of-type-a-meeting-minutes-from-u-s-food-and-5b4963b2) — Source: Acasti Pharma
- 2026-06-18 12:00 EST — [Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update](https://biopharmsignal.com/news/ACST/grace-therapeutics-announces-2026-fiscal-year-end-financial-results-provides-bus-86a698f4) — Source: Acasti Pharma